Safety and tolerability of local treatment with iloprost, a prostacyclin analogue, inpatients with Peyronie's disease: A phase I study

BJU International

Volumn 110, Issue 1, 2012, Pages 117-121

  Pavone, Carlo ^a   Napoli, Giancarlo ^a   Caruana, Giovanni ^a   Alonge, Vincenza ^a   Usala, Manuela ^a   Abbadessa, Daniela ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Iloprost; Intralesional therapy; Nonsurgical therapy; Peyronie's disease; Prostaoyclin I2

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; ILOPROST;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FOLLOW UP; HEADACHE; HUMAN; INJECTION SITE BURNING; INJECTION SITE PAIN; MALE; PAIN; PEYRONIE DISEASE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; SINGLE DRUG DOSE; SYSTEMIC DISEASE; TREATMENT PLANNING;

ADULT; AGED; EPOPROSTENOL; FIBRINOLYSIS; HUMANS; ILOPROST; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; PENILE INDURATION;

EID: 84862303493     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10733.x     Document Type: Article

References (29)

1. Gelbard MK. Peyronie's disease. In Ball TP ed. AUA Update Series, Houston, TX: American Urological Association, 2002: 226-31
2. Brock G, Hsu GL, Nunes L, von Heyden B, Lue TF. The anatomy of the tunica albuginea in the normal penis and Peyronie's disease. J Urol 1997; 157: 276-81 (Pubitemid 26414973)
3. Ralph DJ, Mirakian R, Pryor JP et al. The immunological features of Peyronie's disease. J Urol 1996; 155: 159-62 (Pubitemid 126426455)
4. Schiavino D, Sasso F, Nucera E et al. Immunologic findings in Peyronie's disease: a controlled study. Urology 1997; 50: 764-8 (Pubitemid 27495000)
5. Nachtsheim DA, Rearden A. Peyronie's disease is associated with an HLA class II antigen, HLA-DQ5, implying an autoimmune etiology. J Urol 1996; 156: 1330-4 (Pubitemid 26307604)
6. Rompel R, Weidner W, Mueller-Eckhardt G. HLA association of idiopathic Peyronie's disease: an indication of autoimmune phenomena in ethiopatho-genesis? Tissue Antigens 1991; 38: 104-6
7. Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990; 128: 1376-9
8. Ralph DJ, Schwartz G, Moore W et al. The genetic and bacteriological aspects of Peyronie's disease. J Urol 1997; 157: 291-94 (Pubitemid 26414976)
9. Agrawal V, Ellins E, Donald A et al. Sistemic vascular endothelial dysfunction in Peyronie's disease. J Sex Med 2008; 5: 2688-93
10. Devine CJ Jr, Jordan GH, Schlossberg SM. Proposal: trauma as the cause of the Peyronie's lesion. J Urol 1997; 185: 290
11. Jarow JP, Lowe FC. Penile trauma: an etiologic factor in Peyronie's disease and erectile dysfunction. J Urol 1997; 158: 1388-90 (Pubitemid 27391203)
12. Davis CJ. The microscopic pathology of Peyronie's disease. J Urol 1997; 157: 282-4
13. Somers KD, Dawson DM. Fibrin deposition in Peyronie's disease plaque. J Urol 1997; 157: 311-5 (Pubitemid 26414981)
14. Davila HH, Ferrini MG, Rajfer J, Gonzalez-Cadavid NF. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease. BJU Int 2003; 91: 830-8 (Pubitemid 36724070)
15. Gonzalez-Cadavid NF. Mechanisms of penile fibrosis. J Sex Med 2009; 6 (Suppl. 3): 353-62. Review
16. Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S. Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol 2009; 41: 467-71
17. Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study. J Sex Med 2008; 5: 180-7
18. Demey A, Chevallier D, Bondil P, Toubol J, Amiel J. Is intracavernosal corticosteroid infiltration really useless in Peyronie's disease? Prog Urol 2006; 16: 52-7 (Pubitemid 44726030)
19. Novak TE, Bryan W, Templeton L, Sikka S, Hellstrom WJ. Combined intralesional interferon alpha 2B and oral vitamin E in the treatment of Peyronie's disease. J la State Med Soc 2001; 153: 358-63
20. Brake M, Loertzer H, Horsch R, Keller H. Treatment of Peyronie's disease with local interferon-alpha 2b. BJU Int 2001; 87: 654-7 (Pubitemid 34293757)
21. Lamprakopoulos A, Zorzos I, Lykourinas M. The use of betamethasone and hyaluronidase injections in the treatment of Peyronie's disease. Scand J Urol Nephrol 2000; 34: 355-60 (Pubitemid 32066237)
22. Ordi J, Selva A, Fonollosa V, Vilardell M, Jordana R, Tolosa C. Peyronie's disease in systemic sclerosis. Ann Rheum Dis 1990; 49: 134-5 (Pubitemid 20041024)
23. El-Sakka AI, Hassoba HM, Pillarisetty RJ et al. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997; 158: 1391-4
24. Haag SM, Hauck EW, Szardening-Kirchner C et al. Alterations in the transforming growth factor (TGF)-beta pathway as a potential factor in the pathogenesis of Peyronie's disease. Eur Urol 2007; 51: 255-61 (Pubitemid 44821507)
25. Stratton R, Shiwen X, Martini G et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001; 108: 241-50 (Pubitemid 32656248)
26. Abern MR, Levine LA. Peyronie's disease: evaluation and review of nonsurgical therapy. Scientific World Journal 2009; 9: 665-75
27. Paez A, Mejias J, Vallejo J, Romero I, De Castro M, Gimeno F. Grupo Urologico del Suroeste Madrileno (GUSOM). Long-term patient satisfaction after surgical correction of penile curvature via tunical plication. Int Braz J Urol 2007; 33: 502-7; discussion 507-9
28. Kovac JR, Brock GB. Surgical outcomes and patient satisfaction after dermal, pericardial, and small intestinal submucosal grafting for Peyronie's disease. J Sex Med 2007; 4: 1500-8 (Pubitemid 47337700)
29. Weidner W, Schroeder-Printzen I, Weiske W et al. Sexual function in Peyronie's disease: an analysis of 222 patients without previous local plaque therapy. J Urol 1997; 157: 325-8 (Pubitemid 26414984)